2-38075207-C-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PP3_ModeratePP5_Very_Strong
The NM_000104.4(CYP1B1):โc.182G>Aโ(p.Gly61Glu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000308 in 1,579,668 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (โ โ ).
Frequency
Genomes: ๐ 0.00022 ( 0 hom., cov: 34)
Exomes ๐: 0.00032 ( 2 hom. )
Consequence
CYP1B1
NM_000104.4 missense
NM_000104.4 missense
Scores
9
6
1
Clinical Significance
Conservation
PhyloP100: 7.71
Genes affected
CYP1B1 (HGNC:2597): (cytochrome P450 family 1 subfamily B member 1) This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. The enzyme encoded by this gene localizes to the endoplasmic reticulum and metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17beta-estradiol. Mutations in this gene have been associated with primary congenital glaucoma; therefore it is thought that the enzyme also metabolizes a signaling molecule involved in eye development, possibly a steroid. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.916
PP5
Variant 2-38075207-C-T is Pathogenic according to our data. Variant chr2-38075207-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 7730.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-38075207-C-T is described in Lovd as [Pathogenic]. Variant chr2-38075207-C-T is described in Lovd as [Pathogenic]. Variant chr2-38075207-C-T is described in Lovd as [Likely_pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CYP1B1 | NM_000104.4 | c.182G>A | p.Gly61Glu | missense_variant | 2/3 | ENST00000610745.5 | NP_000095.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CYP1B1 | ENST00000610745.5 | c.182G>A | p.Gly61Glu | missense_variant | 2/3 | 1 | NM_000104.4 | ENSP00000478561.1 |
Frequencies
GnomAD3 genomes AF: 0.000217 AC: 33AN: 152256Hom.: 0 Cov.: 34
GnomAD3 genomes
AF:
AC:
33
AN:
152256
Hom.:
Cov.:
34
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000318 AC: 63AN: 198162Hom.: 2 AF XY: 0.000386 AC XY: 42AN XY: 108850
GnomAD3 exomes
AF:
AC:
63
AN:
198162
Hom.:
AF XY:
AC XY:
42
AN XY:
108850
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000317 AC: 453AN: 1427294Hom.: 2 Cov.: 35 AF XY: 0.000345 AC XY: 244AN XY: 707904
GnomAD4 exome
AF:
AC:
453
AN:
1427294
Hom.:
Cov.:
35
AF XY:
AC XY:
244
AN XY:
707904
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000217 AC: 33AN: 152374Hom.: 0 Cov.: 34 AF XY: 0.000201 AC XY: 15AN XY: 74512
GnomAD4 genome
AF:
AC:
33
AN:
152374
Hom.:
Cov.:
34
AF XY:
AC XY:
15
AN XY:
74512
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
0
ALSPAC
AF:
AC:
1
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
40
Asia WGS
AF:
AC:
1
AN:
3478
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:17Uncertain:1Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Glaucoma 3A Pathogenic:7Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 17, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Victorian Clinical Genetics Services, Murdoch Childrens Research Institute | Jun 24, 2022 | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with congenital, juvenile, or adult onset primary open anglet glaucoma 3A (MIM#231300) and anterior segment dysgenesis 6, multiple subtypes (MIM#617315). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0112 - The condition associated with this gene has incomplete penetrance (PMID: 26550445, 19744731). (I) 0115 - Variants in this gene are known to have variable expressivity. Individuals with the same variants have been reported with variable severity and age of onset (PMID: 19744731). (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to glutamic acid. (I) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (63 heterozygotes, 2 homozygotes). (SP) 0309 - An alternative amino acid change at the same position has been observed in gnomAD (v2) (1 heterozygote, 0 homozygotes). (I) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0600 - Variant is located in the annotated p450 domain (DECIPHER). (I) 0704 - Another missense variant comparable to the one identified in this case has limited previous evidence for pathogenicity. The p.(Gly61Arg) variant has been classified as pathogenic by a clinical laboratory in ClinVar. (SP) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been observed in homozygous or compound heterozygous state in many individuals with primary congenital glaucoma, and has been described as hypomorphic due to its residual enzyme activity and reduced penentrance (ClinVar, DECIPHER, PMIDs: 19234632, 19744731). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. This variant has been shown to have 25% of wild type activity and significantly reduced protein expression using fluorimetric and western blot assays on transfected HEK-293T cells (PMID: 19234632). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | May 18, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Biochemical Molecular Genetic Laboratory, King Abdulaziz Medical City | Aug 25, 2019 | - - |
Pathogenic, no assertion criteria provided | curation | Department Of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University | Jun 12, 2024 | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tรผbingen | Feb 01, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Feb 28, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 03, 2022 | Published functional studies demonstrate a damaging effect, specifically, the variant causes reduced enzyme activity and decreased protein stability (Chavarria-Soley et al., 2008; Lopez-Garrido et al., 2010); Known as a Middle Eastern founder mutation (Li et al., 2011); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 32153331, 33745036, 26982174, 27243976, 9463332, 9497261, 31024815, 21854771, 25091052, 19793111, 24591815, 19204079, 18470941, 19643970, 24210336, 21596299, 19234632, 12372064, 26164761, 24099281, 23363883, 25261878, 28448622, 16862072, 30127590, 30207287, 30270463, 31980526, 34426522, 31589614, 15621878, 15037581, 33170892) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2022 | - - |
Anterior segment dysgenesis 6 Pathogenic:2
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2002 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 26, 2024 | - - |
Glaucoma 3, primary infantile, B;C1856439:Glaucoma 3A;C4310623:Anterior segment dysgenesis 6 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 24, 2022 | - - |
Primary congenital glaucoma Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 31, 2024 | Variant summary: CYP1B1 c.182G>A (p.Gly61Glu) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00032 in 198162 control chromosomes in the gnomAD database, including 2 homozygotes. This frequency is not significantly higher than estimated for a pathogenic variant in CYP1B1 causing Primary Congenital Glaucoma (0.00032 vs 0.0043), allowing no conclusion about variant significance. c.182G>A has been reported in the literature in multiple individuals affected with Primary Congenital Glaucoma (Bejjani_1998). These data indicate that the variant is very likely to be associated with disease. The following publication has been ascertained in the context of this evaluation (PMID: 9463332). ClinVar contains an entry for this variant (Variation ID: 7730). Based on the evidence outlined above, the variant was classified as pathogenic. - |
CYP1B1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 09, 2024 | The CYP1B1 c.182G>A variant is predicted to result in the amino acid substitution p.Gly61Glu. This variant in compound heterozygous and homozygous states has been reported to be causative for primary congenital glaucoma (PCG) (Bejjani et al. 1998. PubMed ID: 9463332; Abu-Amero et al. 2015. PubMed ID: 24099281; Micheal et al. 2015. PubMed ID: 25091052; Stoilov et al. 1998. PubMed ID: 9497261). This variant was seen in 78% of the PCG chromosomes analyzed and reported as a common variant in the Saudi Arabian population (Bejjani et al. 1998. PubMed ID: 9463332, reported as 3987G>A change). Functional studies have shown that this variant significantly reduces enzyme activity (Banerjee et al. 2016. PubMed ID: 27243976). This variant is reported in 0.041% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Congenital glaucoma Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | This sequence change replaces glycine, which is neutral and non-polar, with glutamic acid, which is acidic and polar, at codon 61 of the CYP1B1 protein (p.Gly61Glu). This variant is present in population databases (rs28936700, gnomAD 0.04%), including at least one homozygous and/or hemizygous individual. This missense change has been observed in individuals with primary congenital glaucoma (PMID: 9463332, 12372064, 19234632). It is commonly reported in individuals of Saudi and Moroccan ancestry (PMID: 9463332, 12372064, 19234632). This variant is also known as c.3987G>A. ClinVar contains an entry for this variant (Variation ID: 7730). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CYP1B1 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects CYP1B1 function (PMID: 18470941, 19793111, 27243976). For these reasons, this variant has been classified as Pathogenic. - |
Glaucoma 3A;C4310623:Anterior segment dysgenesis 6 Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Coban-Akdemir Lab, University of Texas Health Science Center | - | The affected individual was severely delayed with no communication skills and died at a young age. Since the subject was deceased, we could not perform an ophthalmologic evaluation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Uncertain
D;D;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;D;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;H;.
PrimateAI
Pathogenic
D
Sift4G
Pathogenic
D;D;.
Vest4
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at